$21 Billion Global Ophthalmic Drugs Market: Trend Analysis and Forecast to 2022 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Ophthalmic Drugs Market: Trend Analysis and Forecast to 2022" report to their offering.

Ophthalmic drugs are the drugs designed for the treatment of eye diseases and disorders. This administration of drug can be done by instillation of a cream, an ointment, or a liquid drop preparation in the conjunctiva sac. The correct strength and amount of the drug are selected, and the medication is instilled into the eye or eyes as directed. The main reason of continuously strong interest of scientists in these drugs forms is the problem of a low bioavailability of medicinal substance after the application to the eyeball.

The ability to increase the bioavailability of the active substances, reducing the susceptibility of drug forms to defense mechanisms of the human eye, extending contact time of drug with the cornea, increasing the penetration through the complex anatomical structure of the eye, and providing controlled release of drugs into the eye tissues which allows reducing the drug application frequency, witnesses the importance of ophthalmic drugs among the aging population suffering from eye disorders are some of the factors contributing to the growth in the global ophthalmic drugs market.

The global ophthalmic drugs market is projected to grow with a CAGR between 5.2% and 5.5% over the forecast period of 2016 - 2022 and surpass USD 21 billion by 2022. The key factors driving the growth of ophthalmic drugs market are considered to be increasing geriatric population with rising global population, increase in prevalence of eye disorders, technological advancement, and increasing awareness in healthcare spending.

Moreover, challenges faced by ophthalmic drugs market include absence of health insurance in developing countries regarding eye diseases and lack of awareness among the people regarding eye diseases and disorders in underdeveloped and developing countries. One of the key opportunities for new entrants is securing drugs through a licensing agreement with major players such as Novartis and Bayer, which could boost their growth over the forecast period.

Companies Mentioned:

  • Abbott Healthcare
  • Allergan Plc
  • Bayer
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc.
  • Renegeron
  • Santen Pharmaceuticals Company Ltd.
  • Valeant Pharmaceuticals, Inc.

Key Topics Covered:

1. Report Overview

2. Executive Summary

3. Ophthalmic Drugs Market Overview

4. Global Ophthalmic Drugs Market, by Disease Condition

5. Global Ophthalmic Drugs Market, by Dispense Type

6. Global Ophthalmic Drugs Market, by Region

7. Leading Companies

For more information about this report visit http://www.researchandmarkets.com/research/w374zp/global_ophthalmic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical